Piscataway, NJ, February 1, 2019 – Legend Biotech USA, Inc (“Legend”) announced today that the company has recently joined the American Society for Blood and Marrow Transplantation (ASBMT™) Corporate Council. Representatives from Legend plan to actively participate in ASBMT Corporate Council forums. Participation in the ASBMT Corporate Council provides Legend Biotech with the opportunity to […]
Sandyford, Dublin, March 5, 2019 – Legend Biotech Ireland, Ltd. announces the official opening of the company’s European headquarters (HQ) at 10A Ballymoss Road, Sandyford Business Park, Dublin 18, Ireland. Legend Biotech established their European HQ in Dublin at the end of 2017 and has been focusing primarily on research and development (R & D) […]
Designation based on clinical research in advanced relapsed or refractory multiple myeloma Piscataway, NJ, April 3, 2019 – Legend Biotech today announced that the European Medicines Agency has granted a PRIME (PRIority MEdicines) designation to Janssen-Cilag International N.V. (Janssen) for JNJ-68284528 (JNJ-4528), the company’s investigational B cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) […]
National Academy of Sciences publishes update from three LEGEND-2 study sitesResults support findings from fourth study site previously presented at ASH 2018 Piscataway, NJ, April 15, 2019 – New data from three sites involved in the LEGEND-2 Phase 1/2 open-label study showed that treatment with the investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell […]
Legend announces that second and third milestones relating to the US clinical trial have been achieved. Piscataway, NJ, July 29, 2019 ‐ Legend Biotech is pleased to announce that, according to the terms and conditions of an Agreement with Janssen Biotech, Inc. (Janssen), the second and third milestones relating to the clinical trial in the […]
CARTITUDE-1 (MMY2001, NCT03548207), United States(US) Initial Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528*, a CAR-T Cell Therapy Directed Against BCMA, in Patients with RRMM (Abstract #577) Initial Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in RRMM, Indicates Preferential Expansion of CD8+ T Cell Central Memory […]
Designation based on the ongoing U.S. Phase 1b/2 CARTITIUDE-1 (MMY2001, NCT03548207) study in advanced relapsed or refractory multiple myeloma PISCATAWAY, NJ, DECEMBER 6, 2019 – Legend Biotech USA Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to Janssen Research & Development, LLC (Janssen) for JNJ-68284528 (JNJ-4528), […]
Orlando, FL, December 7, 2019 – Legend Biotech announced today initial results from the Janssen Research &Development, LLC (Janssen)-sponsored Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed and/or […]
Orlando, FL, December 9, 2019 – Legend Biotech reported updated data on the LEGEND-2 (NCT03090659) Phase1/2 open-label, first-in-human study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy, LCAR-B38M, in the treatment of patients with advanced relapsed and/or refractory multiple myeloma (RRMM) in China. LCAR-B38M is a structurally differentiated CAR-T cell therapy containing a […]
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the […]
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.